Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochmair, Maximilian J., Fabikan, Hannah, Illini, Oliver, Weinlinger, Christoph, Setinek, Ulrike, Krenbek, Dagmar, Prosch, Helmut, Rauter, Markus, Schumacher, Michael, Wöll, Ewald, Wass, Romana, Brehm, Elmar, Absenger, Gudrun, Bundalo, Tatjana, Errhalt, Peter, Urban, Matthias, Valipour, Arschang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694976/
https://www.ncbi.nlm.nih.gov/pubmed/33171712
http://dx.doi.org/10.3390/ph13110371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694976/
https://www.ncbi.nlm.nih.gov/pubmed/33171712
http://dx.doi.org/10.3390/ph13110371

Ejemplares similares